DHNP-2001B

DHNP-2001B is a small molecule drug candidate being developed by the South Korean pharmaceutical company Daehan Nupharm for the treatment of gastroesophageal reflux disease (GERD). Currently in the formulation development stage, the asset is part of Daehan Nupharm's digestive system pipeline. As a treatment for GERD, its mechanism of action likely involves the inhibition of gastric acid secretion, typically achieved by targeting the hydrogen/potassium-transporting ATPase (proton pump) in the gastric parietal cells. The 'B' designation in its code name often suggests an incrementally modified drug (IMD) or a specific combination formulation intended to optimize the pharmacokinetic profile or clinical efficacy of existing acid-suppressing agents.